Skip to main content
Defiance International

Published study records

Study records for Thymulin

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

329 study records.

4 evidence-verified · 288 citation-verified · 37 citation-only

Verified records by research setting

  • Human research: 43
  • In vitro: 81
  • In vivo/preclinical: 168
  • Review/meta-analysis: 0
  • Other: 0
Filter study recordsReset filters

Current study records

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.

International journal of immunopathology and pharmacology · 2021

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • Thymulin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma.

Science advances · 2020

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • Thymulin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Protective Effect of PBCA Nanoparticles Loaded with Thymulin Against the Relapsing-Remitting Form of Experimental Autoimmune Encephalomyelitis in Mice.

International journal of molecular sciences · 2019

Study scale: Not reported in the declared source.

Abstract only: Open source record

Product or molecular entity relationships

  • Thymulin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Limitations and uncertainty

Not reported in the declared source.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Immunomodulation of Homeopathic Thymulin 5CH in a BCG-Induced Granuloma Model.

Evidence-based complementary and alternative medicine : eCAM · 2013

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • Thymulin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Limitations and uncertainty

Not reported in the declared source.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vitro · Status: Citation identity verified

Thymulin homeopathic dilutions: immunomodulation in a human multicellular spheroid model

International Journal of High Dilution Research - ISSN 1982-6206 · 2026

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • Thymulin: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

Protective effect of exogenous peroxiredoxin 6 and thymic peptide thymulin on BBB conditions in an experimental model of multiple sclerosis.

Archives of biochemistry and biophysics · 2023

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • Thymulin: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

Effectiveness of interleukin-4 administration or zinc supplementation in improving zinc deficiency-associated thymic atrophy and fatty degeneration and in normalizing T cell maturation process.

Immunology · 2022

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • Thymulin: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

Comparison of Thymulin Activity with Other Measures of Marginal Zinc Deficiency.

Biological trace element research · 2021

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • Thymulin: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

INFLUENCE OF THYMULIN ON THE ACTIVITY GAD AND GABA-T IN THE BRAIN OF 3 MONTH OLD RATS IN CYCLOPHOSPHAMIDE IMMUNOSUPPRESSION

NEUROSCIENCE FOR MEDICINE AND PSYCHOLOGY · 2021

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • Thymulin: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation identity verified

High-diluted thymulin on Ehrlich tumor growth in mice and the importance of tumor microenvironment

International Journal of High Dilution Research - ISSN 1982-6206 · 2021

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • Thymulin: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation identity verified

Precursors of thymic peptides as stress sensors.

Expert opinion on biological therapy · 2020

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • Thymulin: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation identity verified

Lessons Learned from Experimental Human Model of Zinc Deficiency.

Journal of immunology research · 2020

Study scale: Not reported in the declared source.

Citation only: Open source record

Product or molecular entity relationships

  • Thymulin: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

No public summary

No plain-language summary is published in this record. Summary availability is separate from its review status. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.